Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Gastrointestinal disorders – page 18

  • 1 123 clinical trials
  • 490 recruiting
  • 469 conditions
  • 28 countries

Conditions in this area

469 conditions with trials, the busiest first

Colitis ulcerative120Colorectal cancer metastatic105Crohn's disease94Colorectal cancer89Pancreatic carcinoma57Gastric cancer55Oesophageal adenocarcinoma48Systemic scleroderma39Pancreatic carcinoma metastatic35Adenocarcinoma pancreas34Rectal cancer33Oesophageal carcinoma32Sjogren's syndrome29Adenocarcinoma gastric28Ovarian cancer27Non-small cell lung cancer26Breast cancer25Colon cancer25Gastrooesophageal cancer25Cystic fibrosis24Hepatocellular carcinoma18Fallopian tube cancer17Endometrial cancer16Gastroenteropancreatic neuroendocrine tumour disease16+445

Clinical trials in Gastrointestinal disorders

1 123 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 123 clinical trials

Small intestine neuroendocrine tumour

Recruiting

Study on Reducing Side Effects of Lutetium (177Lu) Oxodotreotide in Patients with Advanced Midgut Neuroendocrine Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lutetium (177Lu) Oxodotreotide
  • Sponsor:Grupo Espanol De Tumores Neuroendocrinos

Colorectal cancer

Recruiting

Study Comparing Amivantamab and Drug Combination for Patients with Recurrent or Metastatic Colorectal Cancer Without KRAS/NRAS and BRAF Mutations

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Janssen Cilag International

Rectal cancer

Recruiting

Study Comparing Surgery and Chemoradiotherapy with Capecitabine for Early Rectal Cancer Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Amsterdam UMC Stichting

Systemic scleroderma

Recruiting

Study on the Safety of T-Guard (Dafsolimab Setaritox, Grisnilimab Setaritox) for Patients with Early Diffuse Cutaneous Systemic Sclerosis

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:GRISNILIMAB SETARITOX
  • Sponsor:Philikos B.V.

Adenocarcinoma gastric+2

Recruiting

Study on [18F]FAPI-74 for Better Cancer Imaging in Patients with Esophagogastric and Pancreatic Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:[Al[18F]F]Fapi-74
  • Sponsor:UZ Leuven

Colitis ulcerative+1

Recruiting

Study on Reducing Vedolizumab Dosage for Patients with Inflammatory Bowel Disease

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Vedolizumab
  • Sponsor:Amsterdam UMC Stichting

Lymphoma+6

Recruiting

Study to Find the Right Dose and Safety of Lutetium (177Lu) Edotreotide and Arginine-Lysine in Children with Somatostatin Receptor-Positive Tumors

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:L-Arginine Hydrochloride
  • Sponsor:ITM Solucin GmbH

Inflammatory bowel disease

Recruiting

Title: Study of vedolizumab dose adjustment guided by drug level monitoring in patients with inflammatory bowel disease in remission

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Vedolizumab
  • Sponsor:Amsterdam UMC Stichting

Clostridium difficile colitis+1

Recruiting

Study on Optimizing Antibiotic Treatment for Clostridioides Difficile Infection with Vancomycin Hydrochloride in Adult Patients

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Vancomycin Hydrochloride
  • Sponsor:Fakultni Nemocnice Bulovka

Crohn's disease

Recruiting

Study on the Effectiveness and Safety of Obefazimod for Patients with Moderate to Severe Crohn's Disease After Inadequate Response to Other Treatments

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Obefazimod
  • Sponsor:Abivax

Pancreatic carcinoma metastatic+1

Recruiting

Study of TCR-Modified T Cell Therapy with ANOC-001, ANOC-002, and ANOC-003 for Adults with Advanced Pancreatic Cancer

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:ANOC-001
  • Sponsor:Anocca AB

Crohn's disease

Recruiting

Study on EXL01 for Preventing Crohn's Disease Recurrence After Surgery in Patients

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Exl01
  • Sponsor:Groupe De Recherche Sur Les Maladies Inflammatoires Digestives

Substances studied in this area

The therapies tested most often in Gastrointestinal disorders trials.

Fluorouracil205 clinical trialsOxaliplatin195 clinical trialsCapecitabine108 clinical trialsFolinic Acid83 clinical trialsBevacizumab72 clinical trialsCalcium Folinate67 clinical trialsPembrolizumab57 clinical trialsIrinotecan Hydrochloride Trihydrate52 clinical trialsNivolumab48 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.